Palvella Therapeutics

Price & Volume

Stats

52W Range	$6.20-$29.27
Market Cap	$219.3M
Shares Short	182,844

Financials

Revenue (12 Mos)	$0
Revenue Growth (YoY)	0%
Gross Profit (12 Mos)	$0
Diluted EPS	$1.97

News

Yahoo Finance • 7 days ago

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Yahoo Finance • 9 days ago

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Yahoo Finance • 20 days ago

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Yahoo Finance • last month

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

About

CEO	Mr. Wesley H. Kaupinen
CFO	Mr. Matthew E. Korenberg
Address	125 Strafford Avenue, Wayne, PA, United States, 19087
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	14